Compare GS & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GS | AMGN |
|---|---|---|
| Founded | 1869 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.5B | 251.6B |
| IPO Year | 1998 | 2002 |
| Metric | GS | AMGN |
|---|---|---|
| Price | $913.87 | $465.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 26 | 34 |
| Target Price | ★ $1,030.67 | $431.81 |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 10-13-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.19% | 2.16% |
| EPS Growth | 26.59 | ★ 88.23 |
| EPS | ★ 55.56 | 14.79 |
| Revenue | N/A | ★ $25,424,000,000.00 |
| Revenue This Year | $23.48 | $7.41 |
| Revenue Next Year | $1.27 | $4.59 |
| P/E Ratio | ★ $16.45 | $31.64 |
| Revenue Growth | N/A | ★ 8.83 |
| 52 Week Low | $754.00 | $312.39 |
| 52 Week High | $1,153.99 | $483.99 |
| Indicator | GS | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 62.32 |
| Support Level | $899.00 | $446.45 |
| Resistance Level | $945.83 | $483.99 |
| Average True Range (ATR) | 24.80 | 11.64 |
| MACD | 4.40 | -0.65 |
| Stochastic Oscillator | 69.97 | 60.28 |
Goldman Sachs is a storied financial institution, founded in 1869 and best known for its role as a leading global investment bank. The firm has a significant reach across global financial centers and has been the leading provider of global merger and acquisition advisory services, by revenue, for the past 20 years. Since the global financial crisis, Goldman has expanded its offerings into more predictable, fee-based businesses like asset and wealth management, which contributed roughly 30% of postprovision revenue at the end of 2025. The firm generates revenue from investment banking, global market making and trading, lending, asset management, wealth management, and a small and declining portfolio of consumer credit card loans.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.